TRIL Inhibitors
TRIL inhibitors belong to a distinct chemical class characterized by their unique molecular structure and specific mode of action. These inhibitors are designed to target and modulate the activity of the TRIL protein, which plays a pivotal role in various cellular processes. The TRIL protein, an essential component of certain cellular pathways, influences signal transduction and molecular interactions that are integral to cellular function. TRIL inhibitors are meticulously crafted to bind to the TRIL protein in a precise manner, disrupting its normal function. By doing so, these inhibitors have the potential to affect downstream cellular cascades that are reliant on the proper functioning of TRIL.
The molecular structure of TRIL inhibitors is meticulously optimized to ensure high binding affinity and specificity to the target protein. This unique class of compounds showcases the intricate interplay between chemical design and biological function, highlighting the advancements in understanding protein-ligand interactions. Overall, TRIL inhibitors represent a significant area of research in chemical biology, contributing to our expanding knowledge of cellular processes and molecular modulation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a JAK1 and JAK2 inhibitor that disrupts the JAK/STAT signaling pathway. By inhibiting JAKs, it modulates cytokine receptor-associated signaling. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
Baricitinib is another JAK inhibitor, primarily inhibiting JAK1 and JAK2. By blocking JAKs, it disrupts signaling pathways of various cytokines involved in autoimmune disorders such as rheumatoid arthritis. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that targets B-cell receptor (BCR) signaling. By inhibiting BTK, it interferes with B-cell survival and proliferation, making it effective against B cell malignancies. | ||||||
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
Acalabrutinib is another BTK inhibitor that selectively and irreversibly binds to BTK, suppressing BCR signaling and B cell proliferation. It is used in the research of B cell malignancies like mantle cell lymphoma. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
Idelalisib is a PI3Kδ inhibitor that primarily targets the delta isoform of phosphoinositide 3-kinase. Inhibition of PI3Kδ helps control B cell signaling. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
Venetoclax is a Bcl-2 inhibitor that specifically targets and inhibits the anti-apoptotic protein Bcl-2. By doing so, it promotes apoptosis in cancer cells, particularly those with overactive Bcl-2, as seen in chronic lymphocytic leukemia. | ||||||